Department of Neurology, RKU-University and Rehabilitation Hospitals Ulm, University of Ulm, Ulm, Germany.
Department of Neurology, University Hospital, Technische Universität Dresden, Dresden, Germany.
JAMA Neurol. 2019 May 1;76(5):571-579. doi: 10.1001/jamaneurol.2018.4822.
Moderate hypothermia in addition to early decompressive hemicraniectomy has been suggested to further reduce mortality and improve functional outcome in patients with malignant middle cerebral artery (MCA) stroke.
To investigate whether moderate hypothermia vs standard treatment after early hemicraniectomy reduces mortality at day 14 in patients with malignant MCA stroke.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial recruited patients from August 2011 through September 2015 at 6 German university hospitals with dedicated neurointensive care units. Of the patients treated with hemicraniectomy and assessed for eligibility, patients were randomly assigned to either standard care or moderate hypothermia. Data analysis was completed from December 2016 to June 2018.
Moderate hypothermia (temperature, 33.0 ± 1.0°C) was maintained for at least 72 hours immediately after hemicraniectomy.
The primary outcome was mortality rate at day 14 compared with the Fisher exact test and expressed as odds ratio (ORs) with 95% CIs. Rates of patients with serious adverse events were estimated for the period of the first 14 days after hemicraniectomy and 12 months of follow-up. Secondary outcome measures included functional outcome at 12 months.
Of the 50 study participants, 24 were assigned to standard care and 26 to moderate hypothermia. Twenty-eight were male (56%); the mean (SD) patient age was 51.3 (6.6) years. Recruitment was suspended for safety concerns: 12 of 26 patients (46%) in the hypothermia group and 7 of 24 patients (29%) receiving standard care had at least 1 serious adverse event within 14 days (OR, 2.05 [95% CI, 0.56-8.00]; P = .26); after 12 months, rates of serious adverse events were 80% (n = 20 of 25) in the hypothermia group and 43% (n = 10 of 23) in the standard care group (hazard ratio, 2.54 [95% CI, 1.29-5.00]; P = .005). The mortality rate at day 14 was 19% (5 of 26 patients) in the hypothermia group and 13% (3 of 24 patients) in the group receiving standard care (OR, 1.65 [95% CI, 0.28-12.01]; P = .70). There was no significant difference regarding functional outcome after 12 months of follow-up.
In patients with malignant MCA stroke, moderate hypothermia early after hemicraniectomy did not improve mortality and functional outcome compared with standard care, but may cause serious harm in this specific setting.
http://www.drks.de, identifier DRKS00000623.
在早期去骨瓣减压术的基础上进行中度低温治疗,已被建议进一步降低恶性大脑中动脉(MCA)中风患者的死亡率并改善功能预后。
研究中度低温治疗与早期去骨瓣减压术后的标准治疗相比,是否能降低恶性 MCA 中风患者在第 14 天的死亡率。
设计、地点和参与者:这项随机临床试验于 2011 年 8 月至 2015 年 9 月在德国 6 家具有专门神经重症监护病房的大学医院进行。对接受去骨瓣减压术且符合入选标准的患者进行评估,然后将患者随机分配到标准治疗组或中度低温治疗组。数据分析于 2016 年 12 月至 2018 年 6 月完成。
在去骨瓣减压术后立即进行至少 72 小时的中度低温(温度为 33.0±1.0°C)。
主要结局是与 Fisher 精确检验相比,第 14 天的死亡率,并以 95%置信区间(CI)表示的比值比(ORs)。估计了在去骨瓣减压术后的第 14 天内和 12 个月随访期间,严重不良事件的发生率。次要结局测量指标包括 12 个月时的功能结局。
在 50 名研究参与者中,24 名被分配到标准治疗组,26 名被分配到中度低温治疗组。28 名患者为男性(56%);平均(SD)患者年龄为 51.3(6.6)岁。出于安全考虑,暂停了招募:26 名低温组患者中有 12 名(46%)和 24 名标准治疗组患者中有 7 名(29%)在 14 天内至少发生 1 次严重不良事件(OR,2.05[95%CI,0.56-8.00];P=0.26);在 12 个月时,低温组严重不良事件发生率为 80%(25 名患者中有 20 名),标准治疗组为 43%(23 名患者中有 10 名)(HR,2.54[95%CI,1.29-5.00];P=0.005)。低温组第 14 天的死亡率为 19%(26 名患者中有 5 名),标准治疗组为 13%(24 名患者中有 3 名)(OR,1.65[95%CI,0.28-12.01];P=0.70)。在 12 个月的随访后,功能结局没有显著差异。
在恶性 MCA 中风患者中,与标准治疗相比,早期去骨瓣减压术后进行中度低温治疗并未改善死亡率和功能预后,但在这种特定情况下可能会造成严重伤害。
http://www.drks.de,标识符 DRKS00000623。